Pacific Diabetes Technologies key facts
as of Oct 2026- Developer of hollow glucose sensor devices designed for continuous glucose monitoring and insulin delivery.
- Pacific Diabetes Technologies is valued at approximately $30.7M as of Oct 2026 (last reported valuation).
- It has raised $17.6M across 3 recorded rounds; the latest was Seed Round ($3.4M) in Oct 2025.
- Notable investors include National Institutes of Health, Breakthrough T1D, The Leona M. and Harry B. Helmsley Charitable Trust, National Institute of Diabetes and Digestive and Kidney Diseases, Portland State University Business Accelerator — 6 tracked in total.
- Pacific Diabetes Technologies has filed 5 Form Ds with the SEC since 2021, most recently Nov 2025 ($3.4M sold to 15 investors).
- Status: Privately Held (backing).
Pacific Diabetes Technologies's last reported valuation, Mar 2025. Nothing priced has surfaced since.
- ·Watch Pacific Diabetes Technologies: the Monday email on marks, rounds and moves
Pacific Diabetes Technologies funding rounds
3 roundsPacific Diabetes Technologies valuation
Pacific Diabetes Technologies's last reported valuation was $30.7 million in Mar 2025. No priced round, secondary trade or fund mark has surfaced since.
How much has Pacific Diabetes Technologies raised?
Pacific Diabetes Technologies has raised $17.6 million in total; 3 of its rounds are on record, from 2023 on. The largest on record was a $3.4 million seed round in Oct 2025.
Pacific Diabetes Technologies has filed 5 Form Ds with the SEC since 2021, most recently in Nov 2025 ($3.4 million sold to 15 investors).
Pacific Diabetes Technologies investors
6 investors are on record for Pacific Diabetes Technologies, including National Institutes of Health, Breakthrough T1D, The Leona M. and Harry B. Helmsley Charitable Trust and National Institute of Diabetes and Digestive and Kidney Diseases. The seed round in Oct 2025 drew 15 investors.
About Pacific Diabetes Technologies
Developer of hollow glucose sensor devices designed for continuous glucose monitoring and insulin delivery. The company's device aims to reduce the pain and daily disruption of managing insulin-treated diabetes and automated insulin delivery systems, enabling healthcare professionals to reduce needle trauma, and adhesive irritation, and improve adherence among pediatric and reluctant adult patient
- Sector
- Healthcare
- HQ
- Portland, OR, United States
- Founded
- 2013
- Employees
- 15
- Website
- pacificdt.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.